Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Remzistotug · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| Participants Receiving remzistotug Monotherapy (Arm A) | EXPERIMENTAL | - |
| Participants Receiving remzistotug Plus Dostarlimab (Arm B) | EXPERIMENTAL | - |
| Participants Receiving remzistotug Plus Dostarlimab Plus belrestotug (Arm C) | EXPERIMENTAL | - |
| Participants Receiving Dostarlimab Plus belrestotug (Arm D) | EXPERIMENTAL | - |
| Participants Receiving dostarlimab Plus belrestotug Plus remzistotug (Arm E) | EXPERIMENTAL | - |
| Participants Receiving dostarlimab Plus belrestotug Plus nelistotug (Arm F) | EXPERIMENTAL | - |
| China Cohort: Participants receiving dostarlimab (Arm G) | EXPERIMENTAL | - |
| Participants Receiving GSK5764227 Plus dostarlimab (Arm I) | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| Remzistotug | DRUG | Remzistotug will be administered. |
| Dostarlimab | DRUG | Dostarlimab will be administered. |
| Belrestotug | DRUG | Belrestotug will be administered. |
| Nelistotug | DRUG | Nelistotug will be administered. |
| GSK5764227 | DRUG | GSK5764227 will be administered. |
Inclusion criteria: * A female participant is eligible to participate if she is not pregnant or breastfeeding, and at least 1 of the following conditions applies: * Is not a woman of childbearing potential (WOCBP) or * Is a WOCBP and using a contraceptive method that is highly effective with a...
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Bristol-Myers Squibb Company | BMY | 5 | PHASE3 | ACE-536 |
| AbbVie, Inc. | ABBV | 4 | PHASE3 | Navitoclax, Ruxolitinib |
| Novartis AG Sponsored ADR | NVS | 3 | PHASE3 | Pelabresib, Ruxolitinib |
| Karyopharm Therapeutics, Inc. | KPTI | 4 | PHASE3 | Selinexor, Ruxolitinib |
| Geron Corporation | GERN | 2 | PHASE3 | Imetelstat |
| Merck & Co., Inc. | MRK | 1 | PHASE3 | Bomedemstat |
| Incyte Corporation | INCY | 10 | PHASE2 | Ruxolitinib |
| GSK plc Sponsored ADR | GSK | 2 | PHASE2 | MMB |
| Takeda Pharmaceutical Co. Ltd. Sponsored ADR | TAK | 1 | PHASE2 | Elritercept, Ruxolitinib |
| Eli Lilly and Company | LLY | 1 | PHASE1 | LY3410738, Venetoclax, Azacitidine |
| Disc Medicine, Inc. | IRON | 1 | PHASE1 | DISC-0974 |
| Galecto, Inc. | GLTO | 1 | PHASE2 | GB2064 |
| Prelude Therapeutics, Inc. | PRLD | 1 | PHASE1 | PRT12396 |
| United Therapeutics Corporation | UTHR | 1 | PHASE2 | bomedemstat |
Remzistotug is an investigational small molecule being developed for the treatment of neoplasms, which are abnormal growths of tissue that can be benign or malignant. It is currently in Phase 1 clinical development for advanced solid tumors.
Remzistotug is a small molecule, but its specific molecular target has not been disclosed. It is being studied in oncology for the treatment of advanced solid tumors, though the exact biological pathway it affects is not publicly detailed.
Remzistotug is being developed by GSK plc, a global biopharma company listed on the London Stock Exchange under the ticker GSK. The company is conducting clinical trials to evaluate the drug's safety and efficacy in patients with advanced solid tumors.
Remzistotug is in Phase 1 clinical development. It is an investigational drug, meaning it has not been approved by regulatory authorities and is still undergoing clinical trials to assess its safety, tolerability, and potential efficacy in treating neoplasms.
Remzistotug is being evaluated in a first-time-in-human study (NCT05277051) in participants with advanced solid tumors. This Phase 1 trial is active but not recruiting, with an enrollment of 152 participants across multiple countries including the United States, Australia, Canada, China, France, Japan, South Korea, Spain, and the United Kingdom.
Yes, Remzistotug is also known as GSK4381562. The clinical trial NCT05277051, which is studying this drug, uses the name GSK4381562 in its title. Both names refer to the same investigational small molecule being developed by GSK plc.